Literature DB >> 25425687

Hydrocortisone does not influence glucocorticoid sensitivity of acute lymphoblastic leukemia cells.

Lidewij T Warris1, Marry M van den Heuvel-Eibrink2, Ingrid M Ariës3, Rob Pieters4, Erica L T van den Akker4, Monique L den Boer3.   

Abstract

Entities:  

Keywords:  ALL cells; hydrocortisone; steroid sensitivity

Mesh：

Substances：

Year:  2014        PMID： 25425687      PMCID： PMC4380735          DOI： 10.3324/haematol.2014.112177

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  11 in total

Review 1.  Mineralocorticoid receptors in brain, in health and disease: possibilities for new pharmacotherapy.

Authors:  Michael Kellner; Klaus Wiedemann
Journal:  Eur J Pharmacol       Date:  2008-01-19       Impact factor: 4.432

2.  Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia.

Authors:  R Pieters; D R Huismans; A H Loonen; K Hählen; A van der Does-van den Berg; E R van Wering; A J Veerman
Journal:  Lancet       Date:  1991-08-17       Impact factor: 79.321

3.  'Enough is enough': qualitative findings on the impact of dexamethasone during reinduction/consolidation for paediatric acute lymphoblastic leukaemia.

Authors:  Pam McGrath; Lydia Pitcher
Journal:  Support Care Cancer       Date:  2001-11-16       Impact factor: 3.603

Review 4.  Adverse psychological effects of corticosteroids in children and adolescents.

Authors:  F A Stuart; T Y Segal; S Keady
Journal:  Arch Dis Child       Date:  2005-05       Impact factor: 3.791

Review 5.  Therapy Insight: is there an imbalanced response of mineralocorticoid and glucocorticoid receptors in depression?

Authors:  E Ronald de Kloet; Roel H Derijk; Onno C Meijer
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2007-02

6.  Comparison of the antileukemic activity in vitro of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia.

Authors:  G J Kaspers; A J Veerman; C Popp-Snijders; M Lomecky; C H Van Zantwijk; L M Swinkels; E R Van Wering; R Pieters
Journal:  Med Pediatr Oncol       Date:  1996-08

7.  Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia.

Authors:  M L Den Boer; D O Harms; R Pieters; K M Kazemier; U Gobel; D Körholz; U Graubner; R J Haas; N Jorch; H J Spaar; G J L Kaspers; W A Kamps; A Van der Does-Van den Berg; E R Van Wering; A J P Veerman; G E Janka-Schaub
Journal:  J Clin Oncol       Date:  2003-09-01       Impact factor: 44.544

8.  Resistance to different classes of drugs is associated with impaired apoptosis in childhood acute lymphoblastic leukemia.

Authors:  Amy Holleman; Monique L den Boer; Karin M Kazemier; Gritta E Janka-Schaub; Rob Pieters
Journal:  Blood       Date:  2003-08-14       Impact factor: 22.113

9.  Prednisolone resistance in childhood acute lymphoblastic leukemia: vitro-vivo correlations and cross-resistance to other drugs.

Authors:  G J Kaspers; R Pieters; C H Van Zantwijk; E R Van Wering; A Van Der Does-Van Den Berg; A J Veerman
Journal:  Blood       Date:  1998-07-01       Impact factor: 22.113

10.  Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004).

Authors:  Anjo J Veerman; Willem A Kamps; Henk van den Berg; Eva van den Berg; Jos P M Bökkerink; Marrie C A Bruin; Marry M van den Heuvel-Eibrink; Carin M Korbijn; Elisabeth T Korthof; Karin van der Pal; Theo Stijnen; Margreet H van Weel Sipman; J Fransje van Weerden; Elisabeth R van Wering; Anna van der Does-van den Berg
Journal:  Lancet Oncol       Date:  2009-09-09       Impact factor: 41.316
View more
  1 in total

Review 1.  Corticosteroid Action in the Brain: The Potential of Selective Receptor Modulation.

Authors:  Eva M G Viho; Jacobus C Buurstede; Ahmed Mahfouz; Lisa L Koorneef; Lisa T C M van Weert; René Houtman; Hazel J Hunt; Jan Kroon; Onno C Meijer
Journal:  Neuroendocrinology       Date:  2019-03-19       Impact factor: 4.914
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.